Instituto do Câncer do Estado de São Paulo, University of São Paulo, Sao Paulo, Brazil
Gabriel Berlingieri Polho , Mateus Trinconi Cunha , Erick Menezes Xavier , Jamile Almeida Silva , Cassio Murilo Trovo Hidalgo Filho , Nathália de Souza Del Rey Crusoé , Marcelo Junqueira Atanazio , Vivian Horita , Guilherme Fialho de Freitas , David Queiroz Borges Muniz , Vanderson Geraldo Rocha , Jose Mauricio Mota
Background: HDCT is a potentially curative treatment for pts with aGCT after conventional-dose chemotherapy (CDC). There is scarce evidence of outcomes from aGCT pts treated with HDCT in low and middle-income countries. Methods: We reviewed our institutional database to identify pts with progressive aGCT referred for HDCT following tumor boards. Medical charts were analyzed to extract clinical data. Log-rank was used to compare survival estimates and Cox proportional hazard to determine effects on overall survival (OS). Exploratory correlation and survival trend analysis used synthetic minority oversampling and Spearman’s rho estimated correlations. Results: From 1/2013 to 8/2022, 35 aGCT pts were referred for HDCT. Median age was 28 years (IQR 25-30). Most pts had testicular primary (84%), non-seminoma histology (87%), 1 prior treatment line (62%), poor-risk by IGCCCG (78%), and intermediate to very high-risk by IPFSG (45%). Of these, 32 pts were deemed eligible after initial evaluation, 25 had mobilization chemotherapy, and 21 received ≥1 cycle of HDCT. Reasons for treatment non-fulfillment included progressive disease and/or performance deterioration due to toxicity. HDCT regimen varied, with most pts receiving TI-CE (62%). Most pts had delays ≥1 month (85%) and ≥2 months (52%) in the scheduled treatment. The 1-year and 2-year OS rates were 42% and 38% in the eligible population, while 70% and 62% among those who had ≥ 1 cycle HDCT. No risk factors correlated with OS in the univariate analysis (Table). Exploratory analysis of oversampled pts treated with ≥1 cycle of HDCT showed correlation of poor IGCCCG (p<0.01) and IPFSG (p=0.03) with OS. Time to mobilization (TTM) was larger in poor-risk IGCCCG pts (0.4 vs. 1.7 months, p<0.01). Four deaths were attributed to HDCT. Conclusions: HDCT was feasible at our tertiary center in Brazil, despite some treatment-related deaths. For pts who had at least 1 HDCT cycle, survival outcomes were similar to the established literature. Significant delays in protocol were noted and correlated with prognostic group risk.
Eligible population | ≥1 HDCT cycle | Oversampled population (≥1 HDCT cycle) | |
---|---|---|---|
Age | 0.99 (0.91-1.08) | 1.08 (0.98-1.19) | 1.08 (0.97-1.21) |
IPFSG Intermediate, High, Very High | 2.57 (0.83-7.93) | 3.63 (0.75-17.58) | 6.77 (1.39-32.98) |
IGCCCG Poor | 1.85 (0.54-6.34) | 2.59 (0.32-20.83) | 9.97 (1.24-79.81) |
βhCG | 1.00 (1.00-1.00) | 1.00 (1.00-1.00) | 1.00 (1.00-1.00) |
AFP | 1.00 (0.99-1.00) | 1.00 (0.99-1.00) | 1.00 (1.00-1.00) |
LDH | 0.99 (0.99-1.01) | 0.99 (0.98-1.01) | 0.99 (0.98-1.00) |
TTM | 0.78 (0.55-10.11) | 0.81 (0.55-1.19) | 1.03 (0.75-1.41) |
Time from mobilization to first HDCT | 1.33 (0.64-2.75) | 1.33 (0.64-2.75) | 1.81 (0.84-3.91) |
Time from first to second HDCT | 0.81 (0.11-5.85) | 0.81 (0.11-5.85) | 2.56 (0.71-9.30) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Kohei Shitara
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Ming Lei
2023 ASCO Annual Meeting
First Author: Yelena Y. Janjigian
2023 ASCO Gastrointestinal Cancers Symposium
First Author: Yelena Y. Janjigian